Recursion narrows Q1 loss 42% on efficiency gains; REC-1245, REC-4881 advance clinically

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 5, 2025 · ~2 min read

Key Changes

• high

  Net loss improved 42% to $117.5M (from $202.5M in Q1 2025) as R&D spending fell 32% and G&A fell 37%, driven by no Tempus record purchases this quarter, headcount reductions, and clinical portfolio reprioritization.

  MD&A: Operating Results verify on EDGAR →
• high

  REC-1245 (RBM39 degrader) showed favorable Phase 1/2 safety and PK in 16 patients—no dose-limiting toxicities, mostly Grade 1-2 events, dose-dependent exposure, and target engagement demonstrated. Dose escalation ongoing.

  MD&A: REC-1245 DAHLIA Study verify on EDGAR →
• high

  REC-4881 (MEK1/2) FAP data deepened to 53% median polyp reduction at Week 25 (from 43% at Week 13); FDA engagement initiated for potential registrational study, with regulatory update expected 2H26.

  MD&A: REC-4881 TUPELO Study verify on EDGAR →